Hub : Traits :

Overall health rating

459 significantly associated models · 122 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	74957325	75479163	1	1	1.1e-07	4.9e-06	4.9e-01	98	TYW3
2	1	117211384	118766534	1	1	7.9e-11	1.1e-09	7.8e-01	100	MAN1A2
3	1	155424065	156838141	1	1	2.1e-07	3.8e-07	1.0e+00	100	SEMA4A
4	1	201164764	202607593	2	1	2.3e-10	1.9e-10	1.0e+00	100	LMOD1
5	1	242590540	244345666	3	1	5.8e-11	1.8e-09	1.2e-01	93	SDCCAG8
6	2	64586858	66006558	1	1	6.7e-08	1.3e-06	3.8e-01	97	CEP68
7	2	108372251	110002052	2	1	2.9e-08	2.4e-08	2.2e-01	95	GCC2
8	2	197745121	200117777	3	1	1.3e-09	1.4e-09	1.0e+00	100	MARS2
9	2	207107801	208531683	1	1	1.8e-08	3.8e-08	1.0e+00	100	CPO
10	3	48381826	51077419	27	1	3.5e-17	1.7e-14	5.5e-01	99	RNF123
11	3	70757099	71880670	1	1	2.5e-07	1.8e-07	1.0e+00	100	FOXP1
12	3	135861666	137253713	1	1	2.4e-07	2.5e-06	1.6e-01	91	RP11-731C17.2
13	4	1785025	3943984	9	7	3.3e-14	3.3e-13	1.0e+00	100	C4orf10 GRK4 RNF4
14	4	89947254	91439574	1	1	1.4e-07	5.1e-08	2.1e-02	82	SNCA
15	4	158997448	160525502	1	1	3.7e-08	3.7e-09	1.0e+00	100	FNIP2
16	6	33857525	35542476	2	1	4.4e-08	1.9e-08	1.7e-01	94	C6orf106
17	7	1161158	2972072	1	1	2.8e-10	8.4e-12	4.5e-05	64	MAD1L1
18	8	8165004	10985432	3	2	7.7e-09	3.5e-10	2.6e-03	77	MSRA RP11-375N15.2
19	8	11276542	13120332	1	1	2.2e-07	1.2e-08	4.4e-03	75	LOC100506990
20	8	29996824	31433801	1	1	8.1e-12	7.2e-12	4.0e-03	82	TEX15
21	8	142629143	144179460	1	1	1.7e-10	1.1e-06	3.1e-01	96	TSNARE1
22	9	13891813	15288045	1	1	1.7e-07	2.0e-07	6.5e-02	87	RP11-408A13.4
23	9	95502571	96898436	2	2	1.7e-07	3.6e-08	3.5e-03	72	PHF2 RP11-165J3.6
24	9	126927285	129422783	6	8	1.4e-12	1.2e-12	1.0e+00	100	GOLGA1 PBX3 WDR38
25	10	98926838	100488720	1	1	1.7e-08	4.9e-07	6.9e-02	87	CRTAC1
26	11	64501991	67059499	13	2	1.1e-10	1.0e-07	3.7e-02	85	CTD-3074O7.5 SNX32
27	11	76827992	78216992	1	1	9.7e-08	3.3e-06	4.6e-01	97	AP000580.1
28	11	112486568	113952419	3	1	7.0e-10	5.6e-09	2.3e-01	96	ANKK1
29	12	55746910	57125879	1	1	2.8e-07	7.8e-06	2.6e-02	75	RPS26
30	13	31078511	32595740	1	1	3.1e-08	2.6e-08	2.3e-01	95	B3GALTL
31	14	69027866	70518587	3	1	5.1e-09	3.4e-09	5.2e-02	89	DCAF5
32	15	73524629	74968873	2	2	1.9e-08	3.8e-06	3.6e-02	80	LOXL1-AS1 STOML1
33	16	24614505	25167985	1	1	2.4e-07	2.7e-10	7.3e-05	61	SLC5A11
34	16	29972690	31833122	9	1	3.5e-10	7.9e-11	2.5e-02	88	KAT8
35	16	52772129	54210447	1	1	1.4e-07	2.7e-07	1.3e-07	-5	RBL2
36	16	71070698	72569466	3	1	3.0e-08	8.7e-08	5.5e-01	99	PHLPP2
37	17	1594359	2985816	1	1	1.2e-07	2.5e-07	5.4e-01	99	RP1-59D14.1
38	17	42892795	43383100	1	1	1.1e-07	1.5e-07	3.3e-02	84	NMT1
39	17	47119135	47685050	1	1	1.0e-08	3.5e-10	1.0e-02	83	ZNF652
40	17	65289798	66844411	4	1	7.6e-09	7.7e-09	5.1e-02	89	LINC00674
41	19	1226004	2732986	2	1	2.0e-08	3.6e-09	1.3e-02	82	BTBD2
42	19	18359524	19753882	1	1	2.9e-07	1.1e-05	9.1e-06	-2	AC005932.1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Health satisfaction	5.97	8	1	2.2	0.99	4.1e-06	ANKK1 C6orf106 CTD-3074O7.5 GRK4 LINC00674 LMOD1 RNF123 TSNARE1
Unable to work because of sickness or disability	5.67	4	0	0.0	0.99	1.1e-04	GRK4 LOXL1-AS1 PBX3 SLC5A11
Frequency of tiredness / lethargy in last 2 weeks	5.65	10	3	6.7	0.99	6.0e-08	ANKK1 CPO DCAF5 LMOD1 RNF4 RP11-165J3.6 RP11-731C17.2 RP1-59D14.1 STOML1 TYW3
Body mass index (BMI)	5.63	25	19	42.2	0.95	1.1e-15	BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA PHF2 RNF123 RP11-375N15.2 RP11-408A13.4 RP11-731C17.2 SDCCAG8 SLC5A11 SNCA SNX32 STOML1 TEX15
Qualifications: College or University degree	5.43	15	10	22.2	-0.98	6.4e-13	B3GALTL C4orf10 DCAF5 FNIP2 FOXP1 GRK4 LMOD1 RBL2 RNF123 RP1-59D14.1 SDCCAG8 SLC5A11 SNX32 TEX15 TSNARE1
Leg fat mass (left)	5.36	23	12	26.7	0.92	5.8e-12	ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA PHF2 RNF123 RP11-408A13.4 RP11-731C17.2 SDCCAG8 SLC5A11 SNCA SNX32 TEX15
Leg fat percentage (left)	5.30	24	13	28.9	0.96	2.2e-16	ANKK1 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 DCAF5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA NMT1 PHF2 RNF123 RP11-408A13.4 RP11-731C17.2 RP1-59D14.1 SDCCAG8 SLC5A11 SNX32 TEX15
Leg fat mass (right)	5.29	22	12	26.7	0.93	2.3e-11	ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA PHF2 RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNCA SNX32 TEX15
Leg fat percentage (right)	5.15	22	11	24.4	0.96	4.6e-15	ANKK1 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 DCAF5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 MSRA NMT1 PHF2 RNF123 RP1-59D14.1 SDCCAG8 SLC5A11 SNCA SNX32 TEX15
Qualifications: None of the above	5.07	13	6	13.3	0.98	2.0e-11	B3GALTL C4orf10 FOXP1 GOLGA1 GRK4 PHLPP2 RBL2 RNF123 RPS26 SDCCAG8 SLC5A11 TEX15 TSNARE1
Pain experienced in last month	5.03	8	2	4.4	-0.99	2.3e-06	CPO GOLGA1 MAN1A2 PHLPP2 RNF123 RP11-165J3.6 RP11-731C17.2 TYW3
Long-standing illness, disability or infirmity	5.02	5	0	0.0	1.00	2.3e-07	ANKK1 CTD-3074O7.5 NMT1 PBX3 ZNF652
Arm fat mass (left)	4.99	20	13	28.9	0.93	1.1e-10	ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Arm fat mass (right)	4.97	20	12	26.7	0.93	4.0e-11	ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Whole body fat mass	4.88	21	11	24.4	0.93	9.1e-11	AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Waist circumference	4.87	19	12	26.7	0.94	4.9e-11	AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 PHF2 RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Age at first live birth	4.87	7	1	2.2	-0.99	5.1e-06	GRK4 PHLPP2 RNF123 RNF4 RP11-408A13.4 STOML1 TYW3
Body fat percentage	4.78	20	13	28.9	0.96	2.9e-13	AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 MSRA RNF123 RP1-59D14.1 SDCCAG8 SLC5A11 SNX32 TEX15
Arm fat percentage (left)	4.75	19	15	33.3	0.97	5.5e-14	AC005932.1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 SDCCAG8 SLC5A11 SNX32 TEX15
Arm fat percentage (right)	4.65	20	15	33.3	0.97	1.5e-14	AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RNF123 SDCCAG8 SLC5A11 SNX32 TEX15
Current tobacco smoking	4.50	5	0	0.0	0.99	9.4e-08	FNIP2 MSRA PBX3 SLC5A11 WDR38
Number of self-reported non-cancer illnesses	4.44	4	1	2.2	0.99	1.3e-02	CEP68 GRK4 MAN1A2 ZNF652
Trunk fat mass	4.40	19	10	22.2	0.91	6.3e-09	AC005932.1 ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 MSRA RNF123 SDCCAG8 SLC5A11 SNX32 TEX15
Frequency of unenthusiasm / disinterest in last 2 weeks	4.38	3	0	0.0	0.00	1.0e+00	ANKK1 DCAF5 RP11-165J3.6
Trunk fat percentage	4.23	19	12	26.7	0.88	6.3e-08	AC005932.1 ANKK1 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 RNF123 RP1-59D14.1 SDCCAG8 SLC5A11 SNX32 TEX15 ZNF652
Number of treatments/medications taken	4.22	5	1	2.2	1.00	6.0e-05	FOXP1 LINC00674 RNF123 SDCCAG8 ZNF652
Smoking status: Current	4.21	5	0	0.0	0.98	1.1e-06	FNIP2 GOLGA1 PBX3 SLC5A11 WDR38
BMI	4.19	25	15	33.3	0.93	4.3e-13	ANKK1 BTBD2 C4orf10 C6orf106 CRTAC1 CTD-3074O7.5 FNIP2 FOXP1 GRK4 KAT8 LINC00674 LMOD1 MAD1L1 MAN1A2 MARS2 PHF2 RNF123 RP11-408A13.4 RP11-731C17.2 RPS26 SDCCAG8 SLC5A11 SNX32 STOML1 TEX15
Weight	4.16	20	9	20.0	0.82	8.5e-06	ANKK1 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA PHLPP2 RBL2 RNF123 RP11-408A13.4 SDCCAG8 SLC5A11 SNX32 TEX15
Wheeze or whistling in the chest in last year	4.15	7	1	2.2	1.00	8.3e-07	B3GALTL KAT8 LINC00674 LMOD1 NMT1 RNF123 ZNF652
Smoking Status	3.99	9	1	2.2	0.98	3.8e-10	C6orf106 FOXP1 GRK4 PBX3 RNF123 SLC5A11 SNX32 WDR38 ZNF652
Vascular/heart problems diagnosed by doctor	3.92	16	5	11.1	-0.98	9.4e-11	C4orf10 CEP68 GRK4 KAT8 LMOD1 LOC100506990 MSRA NMT1 RBL2 RP11-375N15.2 RPS26 SLC5A11 SNX32 TEX15 TSNARE1 ZNF652
Age at last live birth	3.85	2	1	2.2	0.00	1.0e+00	LINC00674 RNF123
Alcohol usually taken with meals	3.84	5	2	4.4	-0.97	7.5e-03	FOXP1 LMOD1 RP1-59D14.1 TSNARE1 ZNF652
Taking other prescription medications	3.81	3	2	4.4	0.00	1.0e+00	LINC00674 RNF123 ZNF652
Chest pain or discomfort	3.80	3	0	0.0	0.99	8.2e-04	CPO GRK4 MAN1A2
Hypertension (Self-reported)	3.72	14	5	11.1	0.97	3.9e-09	CEP68 KAT8 LMOD1 LOC100506990 MSRA NMT1 RBL2 RP11-375N15.2 RPS26 SLC5A11 SNX32 TEX15 TSNARE1 ZNF652
Mouth/teeth dental problems: Dentures	3.69	3	0	0.0	0.99	8.6e-03	PBX3 RNF123 RP11-731C17.2
Hip circumference	3.68	16	7	15.6	0.79	3.0e-04	BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MSRA RBL2 RNF123 SDCCAG8 SLC5A11 SNX32 TEX15
Medication for pain relief, constipation, heartburn	3.68	6	0	0.0	-0.99	1.2e-04	C6orf106 CPO LMOD1 RP11-165J3.6 SDCCAG8 TEX15
Financial difficulties in last 2 years	3.66	2	0	0.0	0.00	1.0e+00	KAT8 PBX3
High blood pressure	3.63	14	4	8.9	0.97	7.7e-09	CEP68 KAT8 LMOD1 LOC100506990 MSRA NMT1 RBL2 RP11-375N15.2 RPS26 SLC5A11 SNX32 TEX15 TSNARE1 ZNF652
Pain type(s) experienced in last month: Hip pain	3.52	1	0	0.0	0.00	1.0e+00	CRTAC1
Age at First Birth	3.42	1	1	2.2	0.00	1.0e+00	RNF123
Osteoarthritis (self-reported)	3.40	3	0	0.0	0.00	1.0e+00	NMT1 PBX3 RP11-165J3.6
Qualifications: A levels/AS levels or equivalent	3.39	8	2	4.4	-0.93	9.5e-04	FOXP1 GRK4 RBL2 RNF123 SDCCAG8 SLC5A11 TEX15 TSNARE1
Mood swings	3.37	5	2	4.4	0.99	5.4e-04	ANKK1 AP000580.1 RNF123 RP11-165J3.6 SLC5A11
Alcohol intake frequency.	3.36	9	2	4.4	0.94	2.0e-04	CRTAC1 CTD-3074O7.5 DCAF5 FOXP1 KAT8 RNF123 RNF4 TEX15 TSNARE1
Back pain experienced in last month	3.36	3	0	0.0	0.00	1.0e+00	C6orf106 FNIP2 RPS26
Knee pain experienced in last month	3.35	3	0	0.0	0.00	1.0e+00	KAT8 PHLPP2 SDCCAG8
Diastolic blood pressure, automated reading	3.35	13	10	22.2	0.85	2.2e-04	AP000580.1 KAT8 LMOD1 LOC100506990 MSRA NMT1 PBX3 RNF123 SDCCAG8 SLC5A11 SNX32 TSNARE1 ZNF652
Neuroticism score	3.32	7	5	11.1	0.42	3.5e-01	ANKK1 DCAF5 LOC100506990 MSRA RNF123 RP11-165J3.6 RP1-59D14.1
Cardiovascular Disease	3.31	13	5	11.1	0.96	1.2e-09	ANKK1 C4orf10 CEP68 GRK4 KAT8 LMOD1 MAD1L1 NMT1 RBL2 RPS26 SNX32 TEX15 ZNF652
Medication: Co-codamol	3.29	1	0	0.0	0.00	1.0e+00	RNF123
Qualifications: O levels/GCSEs or equivalent	3.24	3	0	0.0	0.00	1.0e+00	GRK4 RNF123 TSNARE1
Intelligence (Savage-Jansen 2018)	3.22	10	7	15.6	-0.97	5.0e-06	FOXP1 LMOD1 PHLPP2 RBL2 RNF123 RP11-731C17.2 SLC5A11 TEX15 TSNARE1 TYW3
Arm predicted mass (left)	3.22	16	9	20.0	0.60	1.5e-02	C6orf106 CPO FNIP2 KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32
Neck or shoulder pain in last month	3.21	2	0	0.0	0.00	1.0e+00	PHLPP2 SNX32
Impedance of arm (right)	3.20	15	8	17.8	-0.96	3.0e-08	C6orf106 FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA PHF2 RNF123 RP11-408A13.4 RP11-731C17.2 RPS26 SNX32 STOML1 ZNF652
Arm fat-free mass (left)	3.18	15	9	20.0	0.56	3.0e-02	C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32
Pack years adult smoking proportion	3.17	2	0	0.0	1.00	2.2e-03	GRK4 RP1-59D14.1
Impedance of whole body	3.16	16	9	20.0	-0.66	5.6e-03	C6orf106 CPO FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA NMT1 RBL2 RNF123 RP11-731C17.2 RP1-59D14.1 SNX32 STOML1 ZNF652
Impedance of arm (left)	3.14	14	9	20.0	-0.96	8.5e-08	C6orf106 FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA PHF2 RNF123 RP11-731C17.2 RPS26 SNX32 STOML1 ZNF652
Basal metabolic rate	3.14	17	9	20.0	0.52	3.3e-02	BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32 WDR38
Loneliness, isolation	3.12	2	0	0.0	0.00	1.0e+00	LINC00674 RP11-165J3.6
Supplements: Fish oil (including cod liver oil)	3.12	1	0	0.0	0.40	6.0e-01	GRK4
Arm predicted mass (right)	3.11	15	9	20.0	0.55	3.2e-02	C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32
Exposure to tobacco smoke outside home	3.10	4	1	2.2	0.97	3.3e-02	FNIP2 MARS2 RNF123 SDCCAG8
Systolic blood pressure, automated reading	3.09	8	5	11.1	0.92	1.2e-03	CEP68 LOC100506990 MSRA NMT1 RNF123 SLC5A11 SNX32 TSNARE1
Illnesses of siblings	3.08	3	1	2.2	0.00	1.0e+00	KAT8 RBL2 SLC5A11
Arm fat-free mass (right)	3.08	13	10	22.2	0.50	8.4e-02	C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32
Leg fat-free mass (left)	3.05	17	8	17.8	0.53	2.9e-02	BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Leg predicted mass (left)	3.04	18	8	17.8	0.53	2.2e-02	BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 SLC5A11 SNX32 WDR38
Average weekly red wine intake	3.00	5	1	2.2	-0.99	1.6e-03	CTD-3074O7.5 FNIP2 FOXP1 RP1-59D14.1 SLC5A11
Depression (Nagel 2018)	2.97	4	0	0.0	0.99	9.2e-03	ANKK1 DCAF5 PHLPP2 RP11-165J3.6
Miserableness	2.97	6	3	6.7	0.76	7.8e-02	ANKK1 LOC100506990 RNF123 RP11-165J3.6 SDCCAG8 SLC5A11
Mineral and other dietary supplements	2.95	2	0	0.0	0.75	2.5e-01	GRK4 NMT1
Depressed Affect (Nagel 2018)	2.94	4	3	6.7	0.99	1.0e-02	ANKK1 DCAF5 RNF123 RP11-165J3.6
Fed-up feelings	2.94	5	1	2.2	0.99	1.3e-03	ANKK1 DCAF5 RNF123 SLC5A11 TEX15
Shortness of breath walking on level ground	2.94	2	0	0.0	0.00	1.0e+00	LMOD1 PHLPP2
Leg fat-free mass (right)	2.94	15	8	17.8	0.47	8.0e-02	BTBD2 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Verbal and Numeric Reasoning (VNR)	2.92	7	3	6.7	-0.95	1.2e-03	FOXP1 PHLPP2 RBL2 RNF123 RP11-731C17.2 SLC5A11 TEX15
Leg predicted mass (right)	2.92	16	8	17.8	0.49	5.4e-02	BTBD2 C6orf106 CPO KAT8 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Fluid intelligence score	2.89	8	3	6.7	-0.97	6.0e-05	FOXP1 LMOD1 PHLPP2 RBL2 RNF123 SLC5A11 TEX15 TYW3
Neuroticism (2016)	2.87	5	1	2.2	-0.46	4.3e-01	ANKK1 CPO LOC100506990 MSRA RP1-59D14.1
Whole body fat-free mass	2.83	14	9	20.0	0.43	1.3e-01	C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Whole body water mass	2.83	14	9	20.0	0.43	1.3e-01	C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NMT1 PHLPP2 RBL2 RNF123 SLC5A11 SNX32 WDR38
Impedance of leg (right)	2.82	15	10	22.2	-0.55	3.4e-02	C6orf106 CPO KAT8 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 RBL2 RNF123 RP11-731C17.2 RP1-59D14.1 SNX32 ZNF652
Frequency of tenseness / restlessness in last 2 weeks	2.81	6	0	0.0	0.99	8.2e-05	ANKK1 B3GALTL CPO RNF123 RP11-165J3.6 TYW3
Impedance of leg (left)	2.80	17	10	22.2	-0.53	2.9e-02	C6orf106 CPO CRTAC1 KAT8 LMOD1 LOC100506990 MAD1L1 MARS2 MSRA NMT1 RBL2 RNF123 RP11-731C17.2 RP1-59D14.1 SNX32 WDR38 ZNF652
Neuroticism	2.79	7	3	6.7	0.80	3.0e-02	ANKK1 DCAF5 KAT8 RNF123 RP11-165J3.6 RP1-59D14.1 TSNARE1
Neuroticism (Nagel 2018)	2.78	6	2	4.4	0.95	4.3e-03	ANKK1 DCAF5 RNF123 RP11-165J3.6 RP1-59D14.1 TSNARE1
Other serious medical condition/disability diagnosed by doctor	2.78	1	0	0.0	0.00	1.0e+00	ANKK1
Pulse rate, automated reading	2.78	7	5	11.1	-0.15	6.7e-01	C6orf106 FNIP2 LMOD1 PBX3 RBL2 RP1-59D14.1 SLC5A11
Leg pain on walking	2.77	1	0	0.0	0.00	1.0e+00	RNF123
Pack years of smoking	2.76	2	0	0.0	0.00	1.0e+00	GRK4 RP1-59D14.1
Mouth/teeth dental problems	2.74	1	0	0.0	0.00	1.0e+00	SDCCAG8
Hand grip strength (right)	2.72	8	4	8.9	-0.61	6.3e-02	AP000580.1 C6orf106 GOLGA1 LOXL1-AS1 NMT1 PBX3 RBL2 SLC5A11
Worrier / anxious feelings	2.72	3	2	4.4	0.00	1.0e+00	LOC100506990 MSRA RP11-731C17.2
Maternal smoking around birth	2.71	1	1	2.2	0.00	1.0e+00	SLC5A11
Forced expiratory volume in 1-second (FEV1)	2.69	12	3	6.7	-0.82	1.9e-04	AP000580.1 C6orf106 CTD-3074O7.5 FOXP1 GOLGA1 GRK4 KAT8 LOC100506990 MSRA PBX3 RNF123 WDR38
Noisy workplace	2.67	1	0	0.0	0.00	1.0e+00	B3GALTL
Qualifications: nursing, teaching	2.67	3	1	2.2	0.00	1.0e+00	LMOD1 RNF123 SDCCAG8
Sensitivity / hurt feelings	2.62	4	2	4.4	0.99	7.9e-03	ANKK1 DCAF5 PBX3 RP11-165J3.6
Medication: Paracetamol	2.62	2	1	2.2	0.00	1.0e+00	RNF123 SDCCAG8
Medication: Blood pressure	2.62	3	1	2.2	0.00	1.0e+00	LOC100506990 MSRA NMT1
Trunk fat-free mass	2.61	11	9	20.0	0.34	3.1e-01	C6orf106 CPO KAT8 LMOD1 MARS2 NMT1 PHLPP2 RBL2 RNF123 SLC5A11 WDR38
Trunk predicted mass	2.61	11	9	20.0	0.34	3.1e-01	C6orf106 CPO KAT8 LMOD1 MARS2 NMT1 PHLPP2 RBL2 RNF123 SLC5A11 WDR38
Systolic Blood Pressure	2.60	10	6	13.3	0.09	7.4e-01	CEP68 LINC00674 NMT1 PBX3 PHLPP2 RNF123 SLC5A11 SNX32 TSNARE1 ZNF652
Nervous feelings	2.58	5	1	2.2	-0.18	7.7e-01	ANKK1 KAT8 LOC100506990 MSRA TSNARE1
Respiratory disease	2.57	3	1	2.2	0.00	1.0e+00	NMT1 RNF123 ZNF652
Hand grip strength (left)	2.56	7	2	4.4	-0.79	1.9e-02	AP000580.1 FOXP1 GOLGA1 LOXL1-AS1 NMT1 PBX3 SLC5A11
Frequency of depressed mood in last 2 weeks	2.56	2	0	0.0	0.00	1.0e+00	ANKK1 RP11-165J3.6
Medication: Omeprazole	2.56	1	0	0.0	0.00	1.0e+00	C6orf106
Average weekly beer plus cider intake	2.56	2	1	2.2	0.00	1.0e+00	NMT1 RNF123
Angina	2.53	2	0	0.0	0.00	1.0e+00	CPO ZNF652
Stomach or abdominal pain in last month	2.53	1	0	0.0	0.00	1.0e+00	RP11-165J3.6
Standing height	2.53	18	14	31.1	-0.54	3.5e-03	AP000580.1 C4orf10 C6orf106 GRK4 LINC00674 LOC100506990 LOXL1-AS1 MSRA NMT1 PBX3 PHLPP2 RBL2 RP11-165J3.6 RP11-731C17.2 SLC5A11 SNX32 STOML1 ZNF652
High blood pressure (siblings)	2.53	2	0	0.0	0.00	1.0e+00	KAT8 SLC5A11
Financial situation satisfaction	2.53	1	0	0.0	0.00	1.0e+00	RNF123
Medication for cholesterol	2.51	1	0	0.0	0.00	1.0e+00	RBL2
Heart attack	2.50	1	0	0.0	0.00	1.0e+00	ZNF652
Father's age at death	2.50	1	0	0.0	0.00	1.0e+00	LOC100506990
Guilty feelings	2.49	4	1	2.2	0.20	8.0e-01	ANKK1 LOC100506990 MSRA RNF123
Medication for cholesterol, blood pressure or diabetes	2.47	1	0	0.0	0.00	1.0e+00	ZNF652
Heart attack/myocardial infarction (self-reported)	2.46	1	0	0.0	0.00	1.0e+00	ZNF652
Emphysema/chronic bronchitis	2.45	1	0	0.0	0.00	1.0e+00	RP11-375N15.2
Medication: Paracetamol	2.44	3	1	2.2	0.00	1.0e+00	NMT1 RNF123 SDCCAG8
Major Depression (MDD)	2.43	1	0	0.0	0.00	1.0e+00	CPO
Forced expiratory volume in 1-second (FEV1), Best measure	2.43	10	1	2.2	-0.77	3.3e-03	AP000580.1 C4orf10 C6orf106 FOXP1 GRK4 KAT8 LOC100506990 MSRA PBX3 RNF123
Irritability	2.43	2	2	4.4	0.00	1.0e+00	LOC100506990 MSRA
Angina (self-reported)	2.41	1	0	0.0	0.00	1.0e+00	ZNF652
Commuting to job workplace: Cycle	2.40	1	0	0.0	0.00	1.0e+00	RP1-59D14.1
Worry too long after embarrassment	2.38	4	2	4.4	-0.20	8.0e-01	ANKK1 LOC100506990 MSRA RP1-59D14.1
Type 2 Diabetes (T2D) (2018)	2.37	5	0	0.0	-0.37	5.4e-01	KAT8 LINC00674 RBL2 RNF123 SNX32
Medication: Blood pressure	2.37	3	1	2.2	0.00	1.0e+00	MSRA SNX32 ZNF652
Tense / 'highly strung'	2.36	4	1	2.2	0.29	7.1e-01	ANKK1 KAT8 LOC100506990 RP11-165J3.6
Seen doctor (GP) for nerves, anxiety, tension or depression	2.35	3	0	0.0	0.00	1.0e+00	ANKK1 B3GALTL CTD-3074O7.5
Peak expiratory flow (PEF)	2.31	5	1	2.2	-1.00	6.2e-05	AP000580.1 GOLGA1 LOC100506990 MSRA RP11-375N15.2
Schizophrenia vs Biploar Disorder	2.30	1	0	0.0	0.00	1.0e+00	LMOD1
Forced vital capacity (FVC)	2.25	11	3	6.7	-0.77	1.2e-03	AP000580.1 C6orf106 CTD-3074O7.5 FOXP1 GOLGA1 GRK4 KAT8 LOC100506990 LOXL1-AS1 RBL2 RNF123
Medication: Bendroflumethiazide	2.24	2	1	2.2	0.00	1.0e+00	LOC100506990 TEX15
Age when periods started (menarche)	2.18	4	1	2.2	-0.31	6.9e-01	RNF123 RNF4 RPS26 SNX32
Diabetes diagnosed by doctor	2.17	1	0	0.0	0.00	1.0e+00	RBL2
Medication: Metformin	2.16	1	0	0.0	0.00	1.0e+00	MAD1L1
Height	2.14	16	14	31.1	-0.32	1.6e-01	AP000580.1 C6orf106 GCC2 GRK4 LINC00674 LOXL1-AS1 NMT1 PBX3 PHLPP2 RBL2 RP11-165J3.6 RP11-731C17.2 SLC5A11 SNX32 STOML1 ZNF652
Number of operations (self-reported)	2.14	1	0	0.0	0.00	1.0e+00	RNF123
Medication: Cholesterol lowering	2.13	1	0	0.0	0.00	1.0e+00	KAT8
Asthma (self-reported)	2.13	1	1	2.2	0.00	1.0e+00	ZNF652
Medication: Aspirin	2.12	2	0	0.0	0.00	1.0e+00	CPO LMOD1
Supplements: Glucosamine	2.10	1	0	0.0	0.00	1.0e+00	NMT1
Triglycerides	2.09	3	1	2.2	0.00	1.0e+00	KAT8 LOC100506990 ZNF652
Diabetes (self-reported)	2.09	2	0	0.0	0.00	1.0e+00	RBL2 RNF123
Asthma	2.09	2	1	2.2	0.00	1.0e+00	NMT1 ZNF652
Medication: Seretide 50 evohaler	2.09	2	0	0.0	0.00	1.0e+00	RNF123 ZNF652
Reason for reducing amount of alcohol drunk: Health precaution	2.08	1	0	0.0	0.00	1.0e+00	RPS26
Forced vital capacity (FVC), Best measure	2.06	8	1	2.2	-0.93	8.8e-05	AP000580.1 C4orf10 FOXP1 GRK4 KAT8 LOXL1-AS1 RBL2 RNF123
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.03	2	1	2.2	0.00	1.0e+00	KAT8 RNF123
Medication: Aspirin	2.02	1	0	0.0	0.00	1.0e+00	LMOD1
Pulse rate	1.97	2	0	0.0	0.00	1.0e+00	FNIP2 RBL2
Worry (Nagel 2018)	1.96	4	2	4.4	0.57	4.3e-01	ANKK1 KAT8 RP11-165J3.6 TSNARE1
Average weekly fortified wine intake	1.95	1	0	0.0	0.00	1.0e+00	SLC5A11
Allergy	1.95	6	2	4.4	-0.12	8.1e-01	AP000580.1 C6orf106 MARS2 NMT1 RPS26 ZNF652
Ever highly irritable/argumentative for 2 days	1.93	1	0	0.0	0.00	1.0e+00	RNF123
Hearing difficulty/problems: Yes	1.92	1	0	0.0	0.00	1.0e+00	CPO
Pulse wave reflection index	1.87	1	0	0.0	0.00	1.0e+00	PBX3
Exposure to tobacco smoke at home	1.85	1	1	2.2	0.00	1.0e+00	RNF123
Coronary Artery Disease (CAD)	1.84	1	0	0.0	0.00	1.0e+00	LMOD1
Qualifications: CSEs or equivalent	1.83	2	0	0.0	0.00	1.0e+00	FNIP2 RNF123
Medication: Ventolin 100micrograms inhaler	1.82	1	0	0.0	0.00	1.0e+00	ZNF652
Allergy or Eczema	1.81	6	3	6.7	-0.05	9.2e-01	AP000580.1 C6orf106 MARS2 NMT1 RPS26 ZNF652
Cholesterol lowering medication	1.77	2	0	0.0	0.00	1.0e+00	CTD-3074O7.5 KAT8
Ever unenthusiastic/disinterested for a whole week	1.76	1	0	0.0	0.00	1.0e+00	RNF123
Comparative body size at age 10	1.76	6	2	4.4	0.72	1.1e-01	LOC100506990 MARS2 MSRA RP11-165J3.6 SNX32 ZNF652
Hayfever, allergic rhinitis or eczema	1.75	4	2	4.4	-0.56	4.4e-01	C6orf106 MARS2 RPS26 ZNF652
Eye problems/disorders: Glaucoma	1.75	1	0	0.0	0.00	1.0e+00	TEX15
Schizophrenia (2014)	1.74	1	0	0.0	0.00	1.0e+00	MARS2
Alcohol intake versus 10 years previously	1.73	1	0	0.0	0.00	1.0e+00	RNF123
HDL Cholesterol	1.69	2	1	2.2	0.00	1.0e+00	C6orf106 CEP68
Sitting height	1.69	7	7	15.6	-0.54	8.5e-02	C6orf106 GRK4 LOXL1-AS1 NMT1 PBX3 RBL2 ZNF652
Comparative height size at age 10	1.68	9	4	8.9	-0.17	6.1e-01	ANKK1 C6orf106 LINC00674 LOXL1-AS1 PBX3 PHLPP2 RBL2 RP11-731C17.2 STOML1
Chronic bronchitis/emphysema (mother)	1.66	1	0	0.0	0.00	1.0e+00	RNF123
Body Mass Index (BMI) (2010)	1.65	1	0	0.0	0.00	1.0e+00	LMOD1
Number of live births	1.61	2	0	0.0	0.00	1.0e+00	MAN1A2 RP11-408A13.4
Waist Hip Ratio (WHR)	1.59	6	2	4.4	0.35	5.0e-01	C6orf106 GRK4 MARS2 PBX3 RBL2 WDR38
Crohns Disease (2012)	1.56	2	0	0.0	0.00	1.0e+00	MARS2 RNF123
Lung FVC	1.56	8	5	11.1	0.22	5.0e-01	C4orf10 C6orf106 CTD-3074O7.5 FOXP1 GRK4 KAT8 LINC00674 RNF123
High cholesterol (Self-reported)	1.56	1	0	0.0	0.00	1.0e+00	RP11-375N15.2
Blood White Count	1.54	10	5	11.1	0.73	3.2e-03	C4orf10 C6orf106 GRK4 KAT8 PBX3 RNF123 SDCCAG8 SLC5A11 TEX15 ZNF652
Hearing difficulty/problems with background noise	1.52	1	0	0.0	0.00	1.0e+00	CPO
Lung FEV1/FVC ratio	1.51	7	4	8.9	0.42	3.5e-01	C6orf106 LINC00674 LMOD1 LOXL1-AS1 PHF2 SLC5A11 ZNF652
Number of incorrect matches in round	1.51	1	1	2.2	0.00	1.0e+00	KAT8
Heel bone mineral density (BMD) T-score, automated (left)	1.49	2	2	4.4	0.00	1.0e+00	LOC100506990 MSRA
Birth weight of first child	1.49	1	0	0.0	0.00	1.0e+00	RBL2
Suffer from 'nerves'	1.48	2	0	0.0	0.00	1.0e+00	ANKK1 LOC100506990
Chronotype (morning person)	1.46	2	1	2.2	0.00	1.0e+00	LMOD1 MARS2
Hayfever/allergic rhinitis (self-reported)	1.45	1	0	0.0	0.00	1.0e+00	MARS2
Schizophrenia (2018)	1.43	2	0	0.0	0.00	1.0e+00	FOXP1 MARS2
Relative age of first facial hair	1.43	1	0	0.0	0.00	1.0e+00	C6orf106
Heel bone mineral density (BMD) T-score, automated (right)	1.43	3	2	4.4	0.00	1.0e+00	LOC100506990 MSRA SLC5A11
Ulcerative Colitis (UC)	1.42	1	1	2.2	0.00	1.0e+00	RNF123
LDL Cholesterol	1.41	1	0	0.0	0.00	1.0e+00	C6orf106
Ulcerative Colitis	1.41	1	0	0.0	0.00	1.0e+00	RNF123
Reaction Time	1.39	1	0	0.0	0.00	1.0e+00	SDCCAG8
Forced expiratory volume in 1-second (FEV1), predicted	1.34	1	1	2.2	0.00	1.0e+00	C6orf106
Irritable Bowel Disease (IBD)	1.33	1	1	2.2	0.00	1.0e+00	RNF123
Birth weight	1.33	1	0	0.0	0.00	1.0e+00	GCC2
Crohns Disease (2017)	1.30	3	0	0.0	0.00	1.0e+00	MARS2 RNF123 SNX32
Medication: Levothyroxine sodium	1.29	1	0	0.0	0.00	1.0e+00	MSRA
Hypothyroidism/myxoedema (self-reported)	1.27	1	0	0.0	0.00	1.0e+00	MSRA
Blood Eosinophil Count	1.22	5	3	6.7	0.43	4.6e-01	LINC00674 NMT1 RPS26 SNX32 ZNF652
Blood Platelet Count	1.22	11	7	15.6	0.43	1.1e-01	AP000580.1 C4orf10 C6orf106 GCC2 GRK4 MARS2 NMT1 PBX3 RP1-59D14.1 SEMA4A SNX32
Alzheimer’s Disease (in mother)	1.20	1	0	0.0	0.00	1.0e+00	KAT8
Rheumatoid Arthritis	1.20	1	0	0.0	0.00	1.0e+00	RPS26
Prostate Cancer	1.16	1	0	0.0	0.00	1.0e+00	RNF123
Breast Cancer	1.15	3	0	0.0	0.00	1.0e+00	CTD-3074O7.5 SEMA4A SNX32
Alzheimer’s Disease (including proxy)	1.09	1	1	2.2	0.00	1.0e+00	KAT8
Eye problems/disorders: None of the above	0.96	1	0	0.0	0.00	1.0e+00	NMT1
Blood Red Count	0.87	10	5	11.1	0.58	2.9e-02	C6orf106 CTD-3074O7.5 DCAF5 KAT8 MARS2 PBX3 PHF2 RP1-59D14.1 RPS26 SEMA4A
Heel T-Score	0.73	9	3	6.7	0.21	5.8e-01	AP000580.1 CTD-3074O7.5 KAT8 LINC00674 NMT1 PHF2 RP11-375N15.2 SLC5A11 SNX32
Tanning	0.33	2	0	0.0	0.00	1.0e+00	PBX3 SDCCAG8
Hair Pigment	0.10	1	0	0.0	0.00	1.0e+00	LINC00674

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cortex	5	0.483	2.4
GTEx	Cells EBV-transformed lymphocytes	5	0.351	2.4
GTEx	Esophagus Gastroesophageal Junction	9	0.623	2.4
GTEx	Prostate	4	0.479	2.4
GTEx	Skin Not Sun Exposed Suprapubic	11	0.447	2.4
GTEx	Small Intestine Terminal Ileum	2	0.434	2.4
GTEx	Spleen	8	0.567	2.4
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.292	2.4
GTEx	Brain Cerebellum	9	0.454	2.3
GTEx	Brain Frontal Cortex BA9	4	0.433	2.3
GTEx	Breast Mammary Tissue	6	0.304	2.3
GTEx	Colon Sigmoid	7	0.479	2.3
GTEx	Esophagus Muscularis	17	0.526	2.3
GTEx	Heart Atrial Appendage	7	0.443	2.3
GTEx	Lung	10	0.348	2.3
GTEx	Ovary	3	0.330	2.3
GTEx	Skin Sun Exposed Lower leg	10	0.275	2.3
GTEx	Stomach	4	0.275	2.3
GTEx	Vagina	2	0.315	2.3
GTEx	Adipose Subcutaneous	12	0.344	2.2
GTEx	Adipose Visceral Omentum	5	0.246	2.2
GTEx	Artery Aorta	7	0.235	2.2
GTEx	Artery Coronary	4	0.338	2.2
GTEx	Artery Tibial	8	0.213	2.2
GTEx	Brain Caudate basal ganglia	2	0.217	2.2
GTEx	Breast Mammary Tissue (Female)	6	0.365	2.2
GTEx	Cells Transformed fibroblasts	15	0.357	2.2
GTEx	Colon Transverse	5	0.242	2.2
GTEx	Esophagus Mucosa	9	0.271	2.2
GTEx	Muscle Skeletal	3	0.104	2.2
GTEx	Nerve Tibial	9	0.208	2.2
GTEx	Pituitary	3	0.269	2.2
GTEx	Testis	5	0.158	2.2
GTEx	Thyroid	16	0.400	2.2
GTEx	Uterus	3	0.529	2.2
GTEx	Whole Blood	10	0.502	2.2
ROSMAP	Brain Pre-frontal Cortex	15	0.342	2.2
CommonMind	Brain Pre-frontal Cortex	12	0.223	2.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	4	0.242	2.2
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	11	0.404	2.2
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	8	0.482	2.2
GTEx	Adrenal Gland	4	0.275	2.1
GTEx	Brain Cerebellar Hemisphere	6	0.403	2.1
GTEx	Brain Putamen basal ganglia	1	0.160	2.1
GTEx	Heart Left Ventricle	4	0.261	2.1
GTEx	Liver	3	0.418	2.1
GTEx	Pancreas	3	0.184	2.1
NTR	Blood	5	0.208	2.1
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	5	0.456	2.1
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.294	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	14	0.342	2.1
The Cancer Genome Atlas	Brain Lower Grade Glioma	16	0.372	2.1
The Cancer Genome Atlas	Lung Adenocarcinoma	8	0.272	2.1
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	4	0.251	2.1
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	2.1
The Cancer Genome Atlas	Testicular Germ Cell Tumors	5	0.391	2.1
The Cancer Genome Atlas	Thyroid Carcinoma	14	0.271	2.1
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.197	2.1
GTEx	Brain Nucleus accumbens basal ganglia	3	0.347	2.0
GTEx	Breast Mammary Tissue (Male)	1	0.084	2.0
METSIM	Adipose	6	0.130	2.0
YFS	Blood	5	0.108	2.0
The Cancer Genome Atlas	Breast Invasive Carcinoma	8	0.182	2.0
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	2.0
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	6	0.293	2.0
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	4	0.160	2.0
The Cancer Genome Atlas	Prostate Adenocarcinoma	14	0.303	2.0
The Cancer Genome Atlas	Rectum Adenocarcinoma	3	0.434	2.0
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.281	2.0
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	2.0
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.238	2.0
GTEx	Brain Hippocampus	0	0.000	1.9
GTEx	Brain Hypothalamus	1	0.169	1.9
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	1.9